It is a NEW DAY in DME

Diabetic macular edema affects over 700,000 American adults over the age of 40. A DME diagnosis can be concerning, but there are medical treatments available which could slow or reverse the effects of DME. 

The NEW DAY Study is a clinical research trial looking at the benefits of short- vs. long-acting therapies for DME. This article describes the study and how you may be able to participate. If you have additional questions about DME or the study, you should consult with your doctor.


What Is the NEW DAY Study?

The NEW DAY Study is a clinical research study that compares long-acting and short-acting treatment options for DME. Because DME can be treated through both long- and short-acting therapies, the NEW DAY Study seeks to understand how to use both options to improve DME patient outcomes. 

The short-acting treatment for DME evaluated in the study involves anti-VEGF (vascular endothelial growth factor) injections. These eye injections may prevent further vision loss and can sometimes improve vision by slowing the growth of abnormal blood vessels in the eye. Over the course of the anti-VEGF treatment, patients receive multiple injections to treat DME. 

Longer-acting treatments for DME involve injecting a corticosteroid implant into the back of the eye. One option releases low doses of the corticosteroid, fluocinolone acetonide, into the retina for an extended period of time.

Both long- and short-acting injections help treat DME, but researchers and doctors want to understand how effective each option is in early DME cases. The NEW DAY Study compares the two treatment options to provide patients and doctors with more information to help them determine the best treatment plan for each DME patient. 


There Are Three Steps to the NEW DAY Study Enrollment

Step 1: Complete the Pre-Qualification Survey

To see if you qualify to participate in this study, you must first fill out a brief survey. Questions on this survey include: 

  • If you’ve been diagnosed with diabetes, have you experienced issues with your vision, or have you been diagnosed with DME? 
  • Have you ever been treated for DME? 
  • Have you ever been told you have glaucoma? 
  • Are you willing to visit your doctor once a month for the duration of the 18-month study? 


After completing the questionnaire, you will be notified whether you can be considered for participation in the study.

Step 2: Find a Study Site

Once you’ve filled out the survey, check and see if your current doctor is participating in the NEW DAY Study. If they are not, you can find the closest participating doctor near you. 

Step 3: Visit the Office

Now that you have found a doctor, it’s time to schedule an in-person appointment to talk with them about your interest in the NEW DAY Study. If the doctor is participating in the research study, they’ll be able to discuss the study in more detail. 


How Do You Know if You Qualify for the NEW DAY Study?

You can take the pre-qualification survey on the NEW DAY Study website to see if you’re eligible for participating in this study. It’s a short, simple questionnaire, and it helps you easily identify if you meet the qualifications to be a part of the study.  

The NEW DAY Study could be beneficial for your specific case of DME. If you answer yes to one or more of the following statements, you might qualify to participate in the NEW DAY Study.

  • You have been recently diagnosed with DME.
  • It’s been at least 12 months since your last DME treatment appointment.
  • You are currently seeking medical treatment for your DME.

Why Should You Participate in This Clinical Research Study?

This clinical research study provides doctors and researchers with more information on which treatment options best serve DME patients. With the knowledge gained from the NEW DAY Study, researchers can evaluate long- and short-acting treatments, and then they can determine the most appropriate treatment plan for DME patients.
The rights and safety of patients are protected during this study, and if you participate, you would be helping further the research on how to treat early diabetic macular edema.


FAQs About the NEW DAY Study

What Is the Purpose of the NEW DAY Study?

The purpose of this study is to compare a long-acting treatment of corticosteroid – fluocinolone acetonide – to short-acting anti-VEGF injections. The goal is to understand which treatment works best as a first-line therapy for DME. 

How Long Does the Study Last? 

The study lasts 18 months once you are qualified to participate. 

What Is the Time Commitment to the Study?

You must meet with your doctor every month during the 18 months of the study period. 

Will I Be Compensated for Participating in the Study?

If you qualify to participate in the study, you will be compensated for travel and time expenses. 

What COVID-19 Protocols Do You Have in Place?

Participant’s safety is protected during the study. Your doctor will ensure the proper protocols are in place during the study, and they will work to ensure your safety is prioritized. 

If you have additional questions about the study, you can email us at You can also visit to understand broader questions relating to clinical research studies. 


Is the NEW DAY Study Right for You? 

If you have DME or think you might qualify for DME treatment, contact your doctor today to discuss treatment options and possible participation in the NEW DAY Study. Your participation in this study could help further the research on how to best treat DME for future patients.

If you want to learn more about DME and the various treatment options, click here to visit the dme&me site. You can also read more about the NEW DAY Study by following this link. 


DME and ME